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Context: Familial dysalbuminemic hyperthyroxinemia, characterized by abnormal circulating al-
buminwith increasedT4affinity, causesartefactual elevationof freeT4 concentrations ineuthyroid
individuals.
Objective: Four unrelated index cases with discordant thyroid function tests in different assay
platforms were investigated.
Design and Results: Laboratory biochemical assessment, radiolabeled T4 binding studies, and ALB
sequencing were undertaken. 125I-T4 binding to both serum and albumin in affected individuals was
markedly increased, comparable with known familial dysalbuminemic hyperthyroxinemia cases. Se-
quencing showedheterozygosity foranovelALBmutation (arginine to isoleucineat codon222,R222I)
in all four cases and segregation of the genetic defect with abnormal biochemical phenotype in one
family.Molecularmodeling indicates that arginine 222 is locatedwithin a high-affinity T4 binding site
in albumin, with substitution by isoleucine, which has a smaller side chain predicted to reduce steric
hindrance, thereby facilitating T4 and rT3 binding. When tested in current immunoassays, serum free
T4 values from R222I heterozygotes were more measurably abnormal in one-step vs two-step assay
architectures. Total rT3 measurements were also abnormally elevated.
Conclusions: A novel mutation (R222I) in the ALB gene mediates dominantly inherited dysalbu-
minemic hyperthyroxinemia. Susceptibility of current free T4 immunoassays to interference by this
mutant albumin suggests likely future identification of individuals with this variant binding
protein. (J Clin Endocrinol Metab 99: E1381–E1386, 2014)
Familial dysalbuminemic hyperthyroxinemia (FDH),themost common heritable cause of elevated total T4
levels in euthyroid subjects, has an estimatedprevalence of
1 in 10 000 individuals (1). Consistent with its dominant
inheritance, the disorder is associated with heterozygous
albumin (ALB) gene defects, generating mutant proteins
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with enhanced T4 binding affinity. An arginine-to-histi-
dine mutation at residue 218 (R218H) was first described
(2, 3) and is the most common causal variant in Cauca-
sians but also recognized inHispanic/PuertoRican (4) and
Chinese (5) cases. Substitution of proline for arginine at
the same codon (R218P), resulting in markedly elevated
T4 concentrations, has been described in Japanese and
Swiss subjects (6, 7). A third albumin mutation (L66P),
identified in a Thai kindred, is associated with predomi-
nant elevation of T3 concentrations (8).
Here we describe a novel, heterozygous ALB defect,
with substitution of isoleucine for arginine at codon 222
(R222I) in three African (Somali) subjects and one East
European (Croatian) family, identified on the basis of dis-
crepant thyroid function tests, with hyperthyroxinemia.
Enhanced T4 binding to this albumin variant correlates
with molecular modeling showing that this amino acid
change likely reduces steric hindrance within its high-af-
finityT4bindingpocket. Elevated freeT4measurements in
most commonly used immunoassay platforms suggests
that additional cases harboring this novel FDH variant
will be identified.
Patients and Methods
Methods
All investigationswere part of an ethically approved protocol
and/or clinically indicated, being undertaken with the consent
from patients and/or next of kin.
Biochemical measurements
Thyroid hormones [free T4 (FT4) and free T3] and TSHwere
measured using automated immunoassay systems (Advia Cen-
taur; Siemens; Wallac DELFIA Ultr; PerkinElmer; Access; Beck-
man-Coulter; Elecsys; Roche Diagnostics; Architect; Abbott Di-
agnostics). T4 binding globulin (TBG) was measured by
immunoassay (Siemens Immulite). Equilibriumdialysis FT4was
measured by RIA (Quest Diagnostics). Total T3 and rT3 were
measured in deproteinized samples by separation using C18 col-
umn chromatography followed by electrospray mass spectrom-
etry or (rT3 in a subset of cases) by competitive RIA (Quest
Diagnostics).
Radiolabeled T4 binding studies and gel
electrophoresis
Serum binding of 125I-T4 was assayed with excess cold T4 to
saturate binding sites on TBG as described previously (9); inclu-
sion of cold rT3 in this assay enabled comparison of its binding
with R218H and R222I albumin mutants. 125I-T4 binding to
serum proteins was analyzed by gel electrophoresis (MayoMed-
ical Laboratories) as described previously (10).
Albumin gene sequencing
Exons of the human albumin gene were PCR amplified from
genomic DNA using specific primers (listed in Supplemental
Material) and analyzed by Sanger sequencing.
Molecular modeling
The R222I mutant albumin was modeled (Pymol) using pre-
viously describedwild-type albumin (1bm0) albumin-T4 (1hk1),
R218H FDHmutant albumin-T4 (1hk2), and R218P FDHmu-
tant albumin-T4 (1hk3) crystal structures (11), selecting the rota-
mer with the fewest clashes.
Results
Clinical and biochemical features
Proband 1 was a 2.5-year-old, Somalian boy (P1), in-
vestigated for lowweight, was found to have elevated FT4
but unsuppressed TSH (Table 1). His mother and two
siblings exhibited similarly abnormal thyroid function
tests [mother: FT4 36.9 pmol/L, (reference range) [RR]
10–24), TSH 1.57 mU/L (0.5–5.0); sibling 1: FT4 30.9
pmol/L (RR 11–22), TSH 2.01 mU/L (RR 0.4–3.5); sib-
ling 2: FT4 48.5 (12–25), TSH 3 mU/L (RR 0.4–3.5)].
Proband 2was an unrelated 41-year-old Somali male (P2)
and was referred with a similar biochemistry (Table 1).
Proband 3 was a 20-year-old Somali female (P3), investi-
gated for fatigue and weight gain, and showed hyperthy-
roxinemia with nonsuppressed TSH (Table 1). Proband 4
was a 22-year-old Caucasian female (P4) from Croatia,
investigated for asthenia and anxiety, and was found to
have hyperthyroxinemia with nonsuppressed TSH. Her
sibling and father exhibited similar thyroid function tests
[father: FT441.2 pmol/L (RR10–22), TSH3.2mU/L (RR
0.28–4.3); sibling: FT433.5pmol/L (RR10–22),TSH3.0
mU/L (RR 0.28–4.3)].
Although local testing in all probands showed mark-
edly raised FT4 concentrations, FT4 measurements using
the two-stepDELFIAmethodwerequitediscordant, being
near normal; furthermore, FT4 measured by equilibrium
dialysis was normal (Table 1). These observations sug-
gested analytical interference with FT4 measurement,
with diagnostic possibilities including abnormal circulat-
ing thyroid hormone binding proteins. Although total T4
was raised in each proband, the TBG levels were normal
(Table 1). Hence, an albumin protein abnormality was
considered. Serumbinding of 125I-T4 in each probandwas
markedly raised (Table 1), comparablewith values (28%–
44%) in sera from known FDH cases, harboring the
R218H albumin mutation. Gel electrophoresis of serum
from an affected individual identified excess 125I-T4 bind-
ing to albumin [Figure 1A, panel (ii)]. The abnormal elec-
trophoretic profile was similar to the pattern of 125I-T4
binding in serum from a known FDH case, harboring the
R218H albumin mutation [Figure 1A, panel (i)].
Molecular genetic studies
ALB sequencing of probands (P1-P4) revealed
heterozygosity for a single-nucleotide substitution (AGA
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to ATA), corresponding to an arginine to isoleucine
change at codon 222 in the predicted protein sequence,
with no other coding region changes. The mutation is not
present in 100 control DNA samples and normal genome
data sets (dBSNP, 1000 Genomes) including more than
2000 African-American alleles (Exome Variant Server,
NHLBI Exome Sequencing Project, Seattle, WA, http://
evs.gs.washington.edu/EVS/,May 11, 2013). Genotyping
for single-nucleotide polymorphisms around ALB indi-
cates that the Somali cases share an extended haplotype,
suggesting common ancestry, whereas the mutation oc-
curs on a different haplotype background in Caucasian
proband 4 (Supplemental Figure 1).
The mother and siblings of P1, with abnormal thyroid
function tests, were also heterozygous for this nucleotide
change. The ALBmutation cosegregated with phenotype
in family members of P4, being present in individuals (fa-
ther and brother) with elevated FT4 results and serum
125I-T4 binding and absent in her unaffected mother with
normal FT4 concentrations and radiolabeled hormone
binding (Supplemental Figure 2).
FT4, T3, and rT3 measurements in affected cases
The index cases were identified on the basis of discor-
dant FT4 results using one-step (Roche Elecsys or Siemens
Immulite) hormone assays. To investigate the perfor-
mance of commonly used assay platforms, FT4 concen-
trations were measured using sera from ALB R222I
heterozygotes in different two-step [(DELFIA Ultra
(PerkinElmer), Architect (Abbot Diagnostics), Access
(Beckman Coulter)] and one-step [Advia Centaur (Sie-
mensMedical Diagnostics); Elecsys E170 (Roche)] immu-
noassays (Figure1B).Affected individuals exhibited a sim-
ilar pattern, with FT4 measurements being more elevated
in one-step (Centaur, Elecsys) than two-step (Architect,
Delfia) platforms; exceptionally, FT4 values were most
markedly raised with the two-step Beckman Access
method.
We assayed total T3 and rT3 by tandemmass spectrom-
etry using ALB R222I heterozygote sera and compared
concentrations with R218H ALB FDH cases. Total T3
concentrations were slightly raised in two R222I ALB
cases but normal in all other subjects with either variant
albumin (Supplemental Figure 3). In contrast, rT3 con-
centrations were markedly elevated in ALB R222I sera,
being 40- to 70-fold elevated, but were normal or only
marginally raised (1.1-fold) in R218H ALB FDH cases
(Figure 1C). Such elevation was also seen when rT3 was
measured by immunoassay in sera fromR222I FDH cases
(rT3  2 ng/mL, normal range 0.11–0.32 ng/mL). rT3
displaced 125I-T4 binding to R222I ALB sera much more
readily than in control or R218H FDH cases (Supplemen-
tal Figure 4).
Molecular modeling of R222I mutant albumin
In the T4-albumin crystal structure, T4 interacts with
side chains of three residues (R218, W214, and R222)
within a high-affinity binding site. Comparison with an
unoccupied protein structure shows that T4 binding re-
quires significant rearrangement of these three side chains
Table 1. Biochemical Measurements in Index Cases
Proband 1 Proband 2 Proband 3 Proband 4
TSH, mU/L 1.89 1.4 1.71 3.6
Platform Immulite 2000 Roche Elecsys Roche Elecsys Roche Elecsys
Reference rangea 0.3–4.0 0.27–4.2 0.3–4.0 0.28–4.3
FT4, pmol/L 35.3 50.9 39.3 37
Platform Immulite 2000 Roche Elecsys Roche Elecsys Roche Elecsys
Reference rangea 12–25 12–22 9–20 10–22
FT4, pmol/L 21.8 22 20.7 16
Platform DELFIA DELFIA DELFIA DELFIA
Reference range 9–20 9–20 9–20 9–20
FT4 by equilibrium dialysis, ng/dL 2.2 ND 2.1 1.7
Platform Quest ND Quest Quest
Reference rangea 0.8–2.7 ND 1.0–2.4 0.8–2.7
Total T4, nmol/L 303 273 275 204
Platform DELFIA DELFIA DELFIA DELFIA
Reference range 69–141 69–141 69–141 69–141
TBG, g/mL 20.3 20.5 20.6 16.5
Platform Immulite Cisbio Immulite Immulite
Reference range 14–31 11.3–28.9 14–31 14–31
Radiolabeled T4 binding to serum 37% Increased
b 38% 49%
Reference range 20% 20% 20% 20%
Numbers in bold denote that they are outside the reference range. Abbreviation: ND, not done.
a Varying reference data for the same assay platform reflect differing normal ranges used by local laboratories.
b Exact percentage binding unavailable.
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Figure 1. Biochemical studies in FDH cases and molecular modeling of albumin mutation. A, Electrophoregrams showing binding of 125I-T4 to
serum proteins in serum containing an albumin mutation (R218H) known to confer FDH [left panel, (i)] and an individual with hyperthyroxinemia
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(Figure 1D, left panel). Substitution of arginine at codon
222 by isoleucine reduces steric hindrance, enhancing T4
binding (Figure 1D, middle panel). Iodines in the inner
ring ofT4 are in close contactwith side chains ofR222 and
W214. Superimposition of rT3 (Figure 1D, right panel)
with T4, reveals that the absence of an inner ring iodine
would provide more space in the pocket, with both the
isoleucine 222 and tryptophan 214 imposing less steric
hindrance; in contrast, substitutions at R218 are not pre-
dicted to influence rT3 binding.
Discussion
Six individuals from three unrelated families of East Af-
rican and three subjects of Caucasian East European or-
iginwere found to have euthyroid hyperthyroxinemia and
nonsuppressed TSH concentrations, with assay-depen-
dent discordant FT4 measurements suggesting analytical
interference. Normal circulating TBG concentrations to-
gether with increased radiolabeled 125I-T4 binding to se-
rum or albumin from these cases suggested an ALB ab-
normality. Affected individuals are heterozygous for a
missenseALBmutation (R222I); in one kindred, in which
family members were available, heterozygosity for this
ALBmutation segregateswithbothabnormal thyroidbio-
chemical and 125I-T4 binding phenotypes.
The high-affinity binding site for T4 in albumin con-
tains three residues (R218, R222, and W214) whose side
chains undergomarked displacement to accommodate T4
binding (11). Consistent with this structural observation,
substitutionof histidineorprolinewith smaller side chains
for arginine 218 likely reduces steric hindrance, explain-
ing enhancedT4 binding of thesemutant proteins (11, 12).
Likewise,modelingpredicts that substitutionof isoleucine
for arginine 222, as occurs in our cases, also reduces steric
hindrance. Indeed, an artificial albuminmutant (R222M),
with a methionine residue with smaller side chain replac-
ing R222, exhibits increased T4 binding (13).
Our results suggest that, in general, one-step FT4 im-
munoassay methods are more susceptible to interference
by R222I FDH sera than two-step designs. This pattern
resembles differential susceptibility of such assays with
R218H FDH sera (14), presumably reflecting the interac-
tionof labeledT4 analogswith albumin inone-step assays,
which does not occur in two-step or back-titration meth-
ods. It has been suggested that incubation buffer compo-
sition in the Beckman Access assay promotes T4-albumin
interaction, making this two-step method unexpectedly
susceptible to interference (15).
Total T3 concentrationswere raised in twoR222I FDH
sera and normal in R218H FDH cases; this finding is in
accordwithT3 concentrations being raised in only 12%of
R218H FDH (3). In contrast, total rT3 concentrations
were uniformly andmore strikingly elevated inR222I sera
than R218H FDH cases. Previously, raised rT3 was doc-
umented in 50%ofR218HFDHcases (8) and the R218H
mutant albumin binds rT3 with increased affinity (13).
Because total hormone levels likely reflect hormone inter-
actionwith albumin in subjectswithotherwise normalTH
binding proteins, we hypothesized that rT3 binding to
R222I mutant albumin is enhanced, and competition as-
says with radiolabeled T4 confirmed this. Structural mod-
eling suggests a basis for this, with the absence of an inner
ring iodine in rT3, likely to further diminish steric hin-
drance from side chains of residues (Ile 222, Trp 214)
which are in closest proximity to the inner ring iodines.
The biochemical pattern of raised T4, normal T3, and el-
evated rT3 concentrations in R222I FDH resembles that
seen in patients after amiodarone exposure (16), raising
the possibility that this genetic form of FDH might be
confused with other clinical diagnostic possibilities.
In summary, we have identified a novel, heterozygous
ALB mutation (R222I) in subjects of both East African
and Caucasian Eastern European origin. R222I heterozy-
gote sera exhibit a biochemical profile of elevated FT4
concentrations in many current immunoassay platforms,
suggesting that this genetic cause of dysalbuminemic hy-
perthyroxinemia will be readily identified, perhaps in
other populations.
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Figure 1 Continued. and elevated radiolabeled T4 binding to serum containing an R222I albumin mutation [right panel, (ii)]. B, FT4 measured by
various one-step or two-step immunoassays in sera from different cases containing the R222I mutant albumin protein. C, rT3 measured by liquid
chromatography and tandem mass spectrometry in sera from R218H and R222I mutation cases. D, Crystallographic modeling of T4, bound to the
high-affinity T4-binding site in subdomain IIA of the albumin molecule, illustrating the steric constraints imposed on T4 binding. The left panel is a
composite, showing the positions (in yellow) of the side chains of W214, R218, and R222 in the albumin structure not bound to T4, superimposed
on these displaced side chains (white) in the structure of albumin bound to T4. When R222 is replaced by isoleucine (middle panel, in orange), the
shorter side chain presents less steric hindrance to T4 binding. rT3 binding to R222I mutant albumin is also likely to be enhanced (right panel)
because the loss of the inner iodine will further relieve steric hindrance with side chains of residues at positions 222 and 214.
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